DNA甲基化酶3A在动脉粥样硬化中的作用机制

doi:10.3969/j.issn.1673-5765.2021.11.016

摘要/Abstract

摘要： 近来的研究显示，DNA甲基化酶3A（DNA methylase 3 alpha，DNMT3A）在动脉粥样硬化过程中起着重要的调控作用，而动脉粥样硬化是冠心病及缺血性卒中等心脑血管疾病的重要病理基础。体细胞DNMT3A 基因突变可能通过多种免疫细胞、作用机制影响动脉粥样硬化的发生、发展过程，是心脑血管疾病一项尚未明确的重要危险因素。本文重点介绍DNMT3A在心脑血管疾病中的作用机制以及其在心脑血管疾病诊疗中的应用前景。

文章导读： DNMT3A 基因是CHIP中的热点突变之一，可通过多种作用影响动脉粥样硬化，进而造成心脑血管疾病的发
生、发展。目前关于DNMT3A 基因突变在动脉粥样硬化中的作用机制的研究尚处于初期阶段，需要进一步的研究
明确其作用通路。

关键词: DNA甲基化酶3A; 动脉粥样硬化; 心脑血管病; 作用机制; 炎症

Abstract: DNA methylase 3 alpha (DNMT3A) is an important DNA methylation enzyme. Recent studies have shown that it plays an important role in the regulation of atherosclerosis, which is the important pathological basis of cardiovascular and cerebrovascular diseases (CVD), such as coronary heart disease and ischemic stroke. Somatic DNMT3A mutation may affect the occurrence and development of atherosclerosis through several immune cells and mechanisms, and it is an important risk factor for CVD that has not been fully studied. This article focused on the mechanism of DNMT3A in CVD and its application prospect in the diagnosis and treatment of CVD.

Key words: DNMT3A; Atherosclerosis; Cardiovascular and cerebrovascular disease; Mechanism; Inflammation

闫然, 上官艺, 仇鑫, 李子孝. DNA甲基化酶3A在动脉粥样硬化中的作用机制[J]. 中国卒中杂志, 2021, 16(11): 1178-1182.

YAN Ran, SHANGGUAN Yi, QIU Xin, LI Zi-Xiao. Mechanism of DNMT3A in Atherosclerosis[J]. Chinese Journal of Stroke, 2021, 16(11): 1178-1182.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.chinastroke.org.cn/CN/10.3969/j.issn.1673-5765.2021.11.016

https://www.chinastroke.org.cn/CN/Y2021/V16/I11/1178

参考文献

[1] JAISWAL S，FONTANILLAS P，FLANNICK J，et
al. Age-related clonal hematopoiesis associated with
adverse outcomes[J]. N Engl J Med，2014，371（26）：
2488-2498.
[2] JAISWAL S，NATARAJAN P，SILVER A J，et
al. Clonal hematopoiesis and risk of atherosclerotic
cardiovascular disease[J]. N Engl J Med，2017，377
（2）：111-121.
[3] CHALLEN G A，SUN D，JEONG M，et al.
Dnmt3a is essential for hematopoietic stem cell
differentiation[J]. Nat Genet，2011，44（1）：23-31.
[4] GURYANOVA O A，SHANK K，SPITZER B，et
al. DNMT3A mutations promote anthracycline
resistance in acute myeloid leukemia via impaired
nucleosome remodeling[J]. Nat Med，2016，22（12）：
1488-1495.
[5] COLE C B，RUSSLER-GERMAIN D A，
KETKAR S，et al. Haploinsufficiency for DNA
methyltransferase 3A predisposes hematopoietic
cells to myeloid malignancies[J]. J Clin Invest，2017，
127（10）：3657-3674.
[6] CHAVAKIS T，MITROULIS I，HAJISHENGALLIS
G. Hematopoietic progenitor cells as integrative hubs
for adaptation to and fine-tuning of inflammation[J].
Nat Immunol，2019，20（7）：802-811.
[7] BICK A G，PIRRUCCELLO J P，GRIFFIN
G K，et al. Genetic interleukin 6 signaling
deficiency attenuates cardiovascular risk in clonal
hematopoiesis[J]. Circulation，2020，141（2）：124-
131.
[8] MUDERSBACH T，SIUDA D，KOHLSTEDT K，et
al. Epigenetic control of the angiotensin-converting
enzyme in endothelial cells during inflammation[J/
OL]. PLoS One，2019，14（5）：e0216218[2021-02-
02]. https：//doi.org/10.1371/journal.pone.0216218.
[9] SANO S，OSHIMA K，WANG Y，et al. CRISPRmediated
gene editing to assess the roles of Tet2 and
Dnmt3a in clonal hematopoiesis and cardiovascular
disease[J]. Circ Res，2018，123（3）：335-341.
[10] LI X，ZHANG Q，DING Y，et al. Erratum：
methyltransferase Dnmt3a upregulates HDAC9
to deacetylate the kinase TBK1 for activation of
antiviral innate immunity[J]. Nat Immunol，2016，17
（8）：1005.
[11] VERGALLO R，CREA F. Atherosclerotic plaque
healing[J]. N Engl J Med，2020，383（9）：846-857.
[12] CHO K Y，MIYOSHI H，KURODA S，et al. The
phenotype of infiltrating macrophages influences
arteriosclerotic plaque vulnerability in the carotid
artery[J]. J Stroke Cerebrovasc Dis，2013，22（7）：
910-918.
[13] FEIG J E，VENGRENYUK Y，REISER V，et
al. Regression of atherosclerosis is characterized

by broad changes in the plaque macrophage

transcriptome[J/OL]. PLoS One，2012，7（6）：
e39790[2021-02-02]. https：//doi.org/10.1371/journal.
pone.0039790.
[14] MANTOVANI A，GARLANDA C，LOCATI
M. Macrophage diversity and polarization in
atherosclerosis：a question of balance[J]. Arterioscler
Thromb Vasc Biol，2009，29（10）：1419-1423.
[15] JINNOUCHI H，GUO L，SAKAMOTO A，et al.
Diversity of macrophage phenotypes and responses
in atherosclerosis[J]. Cell Mol Life Sci，2020，77
（10）：1919-1932.
[16] MARTINEZ F O，GORDON S，LOCATI M，et al.
Transcriptional profiling of the human monocyte-tomacrophage
differentiation and polarization：new
molecules and patterns of gene expression[J]. J
Immunol，2006，177（10）：7303-7311.
[17] LEONI C，MONTAGNER S，RINALDI A，et
al. Dnmt3a restrains mast cell inflammatory
responses[J/OL]. Proc Natl Acad Sci USA，2017，
114（8）：E1490-E1499[2021-02-02]. https：//doi.
org/10.1073/pnas.1616420114.
[18] MAS-PEIRO S，HOFFMANN J，
FICHTLSCHERER S，et al. Clonal haematopoiesis
in patients with degenerative aortic valve stenosis
undergoing transcatheter aortic valve implantation[J].
Eur Heart J，2020，41（8）：933-939.
[19] ABPLANALP W T，CREMER S，JOHN D，et al.
Clonal hematopoiesis-driver Dnmt3a mutations alter
immune cells in heart failure[J]. Circ Res，2021，128
（2）：216-228.
[20] EID R E，RAO D A，ZHOU J，et al. Interleukin-17
and interferon-gamma are produced concomitantly
by human coronary artery-infiltrating T cells and act
synergistically on vascular smooth muscle cells[J].
Circulation，2009，119（10）：1424-1432.
[21] SMITH E，PRASAD K M，BUTCHER M，et
al. Blockade of interleukin-17A results in reduced
atherosclerosis in apolipoprotein E-deficient mice[J].
Circulation，2010，121（15）：1746-1755.
[22] WIGREN M，BJÖRKBACKA H，ANDERSSON
L，et al. Low levels of circulating CD4+ FoxP3+
T cells are associated with an increased risk for
development of myocardial infarction but not for
stroke[J]. Arterioscler Thromb Vasc Biol，2012，32
（8）：2000-2004.
[23] DINH T N，KYAW T S，KANELLAKIS P，et
al. Cytokine therapy with interleukin-2/antiinterleukin-
2 monoclonal antibody complexes
expands CD4+ CD25+ Foxp3+ regulatory T cells
and attenuates development and progression of
atherosclerosis[J]. Circulation，2012，126（10）：
1256-1266.
[24] KITA T，YAMASHITA T，SASAKI N，et al.
Regression of atherosclerosis with anti-CD3 antibody
via augmenting a regulatory T-cell response in
mice[J]. Cardiovasc Res，2014，102（1）：107-117.
[25] LIESZ A，SURI-PAYER E，VELTKAMP C，et
al. Regulatory T cells are key cerebroprotective
immunomodulators in acute experimental stroke[J].
Nat Med，2009，15（2）：192-199.
[26] SHARMA M，SCHLEGEL M P，AFONSO M
S，et al. Regulatory T cells license macrophage
pro-resolving functions during atherosclerosis
regression[J]. Circ Res，2020，127（3）：335-353.
[27] BRUNIQUEL D，SCHWARTZ RH. Selective，
stable demethylation of the interleukin-2 gene
enhances transcription by an active process[J]. Nat
Immunol，2003，4（3）：235-240.
[28] MAKAR K W，PÉREZ-MELGOSA M，
SHNYREVA M，et al. Active recruitment of
DNA methyltransferases regulates interleukin 4 in
thymocytes and T cells[J]. Nat Immunol，2003，4
（12）：1183-1190.
[29] YU Q，ZHOU B H，ZHANG Y L，et al. DNA
methyltransferase 3a limits the expression of
interleukin-13 in T helper 2 cells and allergic airway
inflammation[J]. Proc Natl Acad Sci USA，2012，109
（2）：541-546.
[30] ABPLANALP W T，MAS-PEIRO S，CREMER
S，et al. Association of clonal hematopoiesis of
indeterminate potential with inflammatory gene
expression in patients with severe degenerative
aortic valve stenosis or chronic postischemic heart
failure[J]. JAMA Cardiol，2020，5（10）：1170-1175.
[31] FUSTER J J，MACLAUCHLAN S，ZURIAGA M
A，et al. Clonal hematopoiesis associated with TET2
deficiency accelerates atherosclerosis development
in mice[J]. Science，2017，355（6327）：842-847.